RxDoctor Payments Data

Jamie Giovanelli, PA

Physician Assistant · Virginia Beach, VANPI 1245791540

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (59.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Teleflex LLC accounts for 93.9% of it on its own, with 8 other manufacturers making up the rest. Among physician assistant clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$117,727in general payments, 2019–2025

Across 384 payments — averaging $306.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$111K
  • SRS Medical Systems, Inc.$7K
  • Boston Scientific$160
  • Sumitomo Pharma America, Inc.$140
  • AbbVie$88
  • I/o Urology Corp.$39
  • plus $91 from 3 others

What the payments were for

  • Consulting fees$21,58118%
  • Speaking & faculty fees$69,51859%
  • Travel & lodging$18,62416%
  • Food & beverage$8,0057%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$117,727 in reported general payments places this provider in the 95th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$207,558
Medicare patients
983
Services billed
5,187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron74$59,664
GemtesaVibegron17$20,943
Tamsulosin Hcl488$6,318
Finasteride459$5,901
Silodosin75$5,691
Trospium Chloride44$4,728
Dutasteride47$2,049
Trimethoprim18$961
Alfuzosin Hcl ErAlfuzosin Hcl28$610
Oxybutynin Chloride ErOxybutynin Chloride27$591
NitrofurantoinNitrofurantoin Macrocrystal24$504
Cephalexin68$394
Cefdinir21$366
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst23$327
Levofloxacin52$134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$140$20,94317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →